Drug Trial Radar · NCT05486104
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
92
Actual
Start
Nov 8, 2022
Primary completion
Dec 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Ganzhou Hemay Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind study. There are three dosage groups: Hemay005 45 mg BID group, 60 mg BID group or placebo group, with 36 patients in each dosage group. All patients will enter a 12-week double-blind treatment period. All subjects who have received the investigational drug should be subjected to a 4-week observation after the end of treatment.
Conditions
- Moderate to Severe Ulcerative Colitis
Interventions
Hemay005 tabletsDrug
Hemay005 tablets (15mg/tablet)will be orally administered twice daily.
Hemay005 placebo tabletsDrug
Hemay005 placebo tablets will be orally administered twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- clinical remissionTime frame: 12 week
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chaoyang Hospital Affiliated to Capital Medical University
Beijing, China
Beijing Friendship Hospital Affiliated to Capital Medical University
Beijing, China
Peking University Third Hospital
Beijing, China
Chongqing People's Hospital
Chongqing, China
Shanghai Oriental Hospital
Shanghai, China
Tianjin Medical University General Hospital
Tianjin, China
The Fourth Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Xiangya Hospital of Central South University
Changsha, Hunan, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Shengjing Hospital Affiliated to China Medical University
Shenyang, Liaoning, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Shandong Provincial Hospital
Jinan, Shandong, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.